Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Functional characterization of SMG1 variants associated with pancreatic cancer susceptibility

FY 2018-19

Summary
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is a devastating and aggressive disease that is often diagnosed in the late stages. Identifying and validating genes which may put individuals at risk for pancreatic cancer may help to aid in surveillance and early intervention for PDAC. Approximately 1 in 10 cases of PDAC are familial, and while some predisposition genes have been identified, they only account for a fraction of the familial PDAC cases. Recent research in our lab suggests that SMG1 may be a novel PDAC predisposing gene, and my proposed research aims to validate this finding. Guided by SMG1 mutations which have been identified in patient populations, I will use CRISPR/Cas9 gene editing technology to introduce targeted mutations into SMG1 into an immortalized pancreatic cell-line. The SMG1 protein product will then be characterized for functional properties and for the ability to drive the formation of a tumour. Overall, my work will help to validate SMG1 as a cancer predisposing gene, which could be implemented into screening programs to identify individuals at risk for pancreatic cancer.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
415334
Name
Lenko Tatiana M
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Functional characterization of SMG1 variants associated with pancreatic cancer susceptibility
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer Genetics; Cancer Predisposition; Crispr/Cas9; Pancreatic Ductal Adenocarcinoma; Smg1
Abstract
Pancreatic cancer, specifically pancreatic ductal adenocarcinoma (PDAC), is a devastating and aggressive disease that is often diagnosed in the late stages. Identifying and validating genes which may put individuals at risk for pancreatic cancer may help to aid in surveillance and early intervention for PDAC. Approximately 1 in 10 cases of PDAC are familial, and while some predisposition genes have been identified, they only account for a fraction of the familial PDAC cases. Recent research in our lab suggests that SMG1 may be a novel PDAC predisposing gene, and my proposed research aims to validate this finding. Guided by SMG1 mutations which have been identified in patient populations, I will use CRISPR/Cas9 gene editing technology to introduce targeted mutations into SMG1 into an immortalized pancreatic cell-line. The SMG1 protein product will then be characterized for functional properties and for the ability to drive the formation of a tumour. Overall, my work will help to validate SMG1 as a cancer predisposing gene, which could be implemented into screening programs to identify individuals at risk for pancreatic cancer.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Lenko, Tatiana M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~